Browse Articles

Discover research articles across all indexed journals

Avelumab in combination with axitinib (Ave + Axi) for first-line (1L) treatment of advanced renal cell carcinoma (aRCC): A systematic literature review (SLR) of real-world effectiveness and safety.

Journal of Clinical Oncology Mairead Kearney, Ankush Taneja, Aniket Sharma et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.491

491 Background: Ave + Axi combination is an approved option worldwide for 1L treatment of patients with aRCC based on the results of the JAVELIN Renal 101 phase 3 trial. The results of the final analysis (data cutoff: Aug 31, 2023) confirmed the long-term efficacy and manageable safety profile of this immunotherapy (IO)/tyrosine kinase inhibitor combination with the longest follow-up (≥68 months in all patients). The aim of this SLR was to summarize the real-world effectiveness, safety, and tolerability of Ave + Axi in aRCC and compare with outcomes from JAVELIN Renal 101. Methods: A SLR was conducted using 3 online databases (MEDLINE, Embase, and Cochrane) to identify publications (to Jul 29, 2024) and recent conference abstracts of Ave + Axi real-world studies reporting outcomes for 1L treatment of aRCC, with no geographical or observational study-type restrictions. Results: A total of 9 studies met the inclusion criteria; most were retrospective (7/9), including multicenter, single-center, or database/registry studies relying on secondary data sources. Studies were conducted in the UK (4/9), Japan (3/9), USA (1/9), and Russia (1/9). Median age was 61.5-70 years; most patients were male (68%-90.5%), had an ECOG performance status of 0-1 (60%-94%), and had metastatic tumors with clear cell histology (66.7%-100%). High attrition between lines of treatment was noted, with only 35% of patients receiving second-line treatment after disease progression (most commonly with cabozantinib monotherapy, 52.2%). Median progression-free survival (PFS) ranged from 9.1-15.3 months (vs 13.9 months in JAVELIN Renal 101). Landmark 1-year PFS and overall survival rates from Ave + Axi start were 27%-68.2% and 15%-98.8%, respectively. Overall response rate was numerically higher in International Metastatic RCC Database Consortium (IMDC) risk favorable- (70.5%) vs intermediate- (64.7%) or poor-risk (39%) subgroups (reported in 1 UK study). Rates of grade ≥3 adverse events (AEs; 17%-36%) and discontinuation due to AEs (10%-27%) were low. Conclusions: Overall, findings from global real-world studies of Ave + Axi in 1L aRCC align with those of the JAVELIN Renal 101 trial, validating the long-term efficacy and safety of this combination. The high rate of attrition between lines of therapy supports the use of the most effective IO-based treatments upfront. Despite the limited number of studies and data heterogeneity, results from this SLR of real-world studies conducted in the IO era in several countries provide a good representation of Ave + Axi use in an evolving treatment landscape. Additional prospective data (eg, the ongoing multi-country AVION study; NCT04941768) and extended follow-up are required to inform the optimal use of Ave + Axi in patient subgroups, such as those with IMDC favorable-risk disease.

Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12).

Journal of Clinical Oncology Arnoud J. Templeton, Stefanie Hayoz, Simone Wyss-Neyer et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.163

163 Background: While reducing skeletal-related events in patients (pts) with bone metastases (BM), bone protecting agents such as DN have adverse events. One major adverse event is osteonecrosis of the jaw (ONJ), which can significantly impact quality of life. The risk of ONJ increases with treatment duration and reaches cumulative rates of up to 9%. We report ONJ rates in a randomized phase III non-inferiority trial investigating the optimal dose schedule of denosumab (DN). Methods: Pts with BM from mCRPC were randomized 1:1 to receive DN every 4 weeks (q4w; arm A, standard arm) versus every 12 weeks (q12w; arm B, experimental arm) after a 16-week induction phase with q4w therapy for both arms. The primary endpoint of the study is time to first symptomatic skeletal event (SSE) while the incidence of ONJ is an important secondary endpoint. Since the differentiation between ONJ and tooth abscess (the term according to CTCAE v5.0 is tooth infection [TI]) can be difficult, we report these two outcomes separately as well as combined (in case both events were reported for one patient, the timepoint of earlier event was counted). An oral inspection at baseline as well as before each application of DN was mandatory. In patients with risk factors for ONJ, a prophylactic dentist visit prior to treatment start was recommended. Data from patients who received at least one dose of DN and who were randomized at least one year before data cut-off (December 11, 2023) were included in this interim safety analysis. As this is an interim analysis, only descriptive analyses were performed without formal statistical comparison between the arms. Results: 546 pts from 39 centers with a median follow-up time of 2.4 years were evaluated for ONJ. The median number of administered DN-doses was 16 doses in arm A and 8 doses in arm B, the treatment duration was 64 weeks in arm A versus 72 weeks in arm B. Rates of ONJ, tooth infection, and the combined rates are given in the table. Time to first ONJ and time to first ONJ or TI was in favor of arm B with HRs 0.63 (95% CI 0.33 - 1.21) and 0.71 (95% CI 0.43 – 1.16), respectively. Conclusions: Administration of DN q12w reduces the risk of ONJ. This risk reduction of ONJ or TI is clinically relevant with an overall absolute difference of 1.6% for all grades and 1.9% for ≥3 after a median follow-up of 2.4 years. Efficacy data for time to first SSE (the primary endpoint of this trial) is not yet mature and will be reported later. Clinical trial information: NCT02051218 . Term Induction phase Arm A (q4w) Arm B (q12w) ONJ, all grades (G) 1/546 (0.2%) 21/242 (8.7%) 15/233 (6.4%) TI, all G 7/546 (1.3%) 13/242 (5.4%) 13/233 (5.6%) ONJ or TI, all G 8/546 (1.5%) 31/242 (12.8%) 26/233 (11.2%) ONJ ≥ G3 0/546 (0%) 12/242 (5.0%) 8/233 (3.4%) TI ≥ G3 1/546 (0.2%) 4/242 (1.7%) 1/233 (0.4%) ONJ or TI, ≥ G3 1/546 (0.2%) 14/242 (5.8%) 9/233 (3.9%)

Chimeric RNA landscape in the Chinese population and the role of <i>SFT2D2-TBX19</i> in prostate cancer progression.

Journal of Clinical Oncology Qiong Wang Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.406

406 Background: Specific gene fusions and their fusion products (chimeric transcripts and proteins) have served as ideal diagnostic markers and therapeutic targets for cancer. However, few systematic studies for chimeric transcriptome have been conducted in prostate cancer (PCa), and none in the Chinese populations. Methods: We analyzed raw RNA-seq data from PCa patients in the Chinese Prostate Cancer Genome Epigenome Atlas (CPGEA) to predict chimeric RNAs using the Eriscript. Fluorescence-activated cell sorting (FACS) was employed to isolate tumor cells, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and T cells from fresh clinical specimens. Cellular functional assays, western blotting, FISH, electron microscopy, RNA pull-down, and immunofluorescence were employed to elucidate the underlying mechanisms by which the chimeric SFT2D2-TBX19 regulates prostate cancer progression. Results: Over 100,000 chimeric RNAs have been predicted in CPGEA. After several rounds of screening, we identified 301 of them with differential expression between cancerous and adjacent normal tissues, and 101 out of them were validated in clinical samples. About 20% showed prognosis correlation, indicating their potential biomarker values. Further experiments found differential expression of those chimeras among cancer epithelial cells, CAFs, TAMs, and T cells. We further examined the effect of these chimeric RNAs, and found examples of chimeric RNAs directly regulates the growth and motility of tumor cells, and regulate communications between tumor cells and their microenvironment, which jointly facilitate tumor progression. An important chimeric RNA, SFT2D2-TBX19 , was identified as encoding the TBX19-202 protein. Both TBX19-202 and its parental TBX19, which share homologous amino acid sequences, enhance prostate cancer cell proliferation, migration and invasion. Additionally, SFT2D2-TBX19 also can work as a lncRNA which could interact with the ATP synthase F1 subunit ATP5F1A, increasing ATP5F1A phosphorylation, which stabilizes the interaction between ATP5F1A and ATP5F1B. The region spanning 1801-2400bp of SFT2D2-TBX19 and the intermediate structural domain of ATP5F1A are crucial functional areas. This stabilization of ATP5F1A and ATP5F1B enhances mitochondrial ATP synthase activity and ATP production, thus maintaining prostate cancer cell proliferation. Conclusions: These findings established the atlas of chimeric transcriptome in PCa from the Chinese populations, and provided a large list of validated chimeric RNAs that have the potentials of becoming novel biomarkers and/or treatment targets. Our research provides comprehensive evidence that the SFT2D2-TBX19 promotes prostate cancer progression by encoding the TBX19-202 protein and stabilizing mitochondrial ATP synthase through ATP5F1A phosphorylation.

Outcome of COVID-19 in patients with idiopathic inflammatory myopathy during the Omicron wave in China: A longitudinal observational study

PLoS ONE Ying Li, Xiaolan Tian, Chao Sun et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0317319

Objective The coronavirus disease pandemic brought unknown challenges to patients with idiopathic inflammatory myopathy, who are often heavily immunosuppressed and have comorbidities. We aimed to investigate the outcomes and risk factors of coronavirus disease in Chinese patients with idiopathic inflammatory myopathy during the Omicron wave. Methods This observational study included patients with idiopathic inflammatory myopathy who visited the China-Japan Friendship Hospital. Data on baseline characteristics and coronavirus disease-related information were collected through medical records and surveys, and subsequently analysed. Results Overall, 204 patients with idiopathic inflammatory myopathy were identified; dermatomyositis was the most common idiopathic inflammatory myopathy subtype. Data were collected from 185 patients with idiopathic inflammatory myopathy who tested positive for severe acute respiratory syndrome coronavirus 2 via polymerase chain reaction or antigen tests; of these, 20 experienced a severe course of the disease, and 9 died. All patients with severe coronavirus disease had idiopathic inflammatory myopathy-associated interstitial lung disease, and the most common antibodies observed in patients with mortality were anti-aminoacyl tRNA synthetase and anti-MDA-5 antibodies. Furthermore, 45.0% of patients in the severe disease group took &gt; 15.0 mg of prednisone daily before infection, a significantly higher proportion than that in the non-severe disease group. Advanced age, mechanics’ hands, dyspnoea, chronic cough and fever during the course of myositis, low lymphocyte count, low serum albumin level, and high D-dimer and ferritin levels before infection were prominent in patients with severe coronavirus disease. Albumin levels below 35.0 g/L and ferritin levels above 306.8 ng/mL were independent risk factors of severe coronavirus disease. Conclusion Omicron did not worsen the overall outcomes of coronavirus disease for patients with idiopathic inflammatory myopathy; however, specific risk factors were identified, highlighting the need for targeted management strategies.

CaV2.3 channels in the mouse central medial thalamic nucleus are essential for thalamocortical oscillations and spike wave discharges

Scientific Reports Vasilije P. Tadic, Tamara Timic Stamenic, Slobodan M. Todorovic Feb 10, 2025 DOI: 10.1038/s41598-025-87795-x

Characteristics and clinical outcomes of metastatic testicular cancer in a distinct demographic.

Journal of Clinical Oncology Ayobami Gbenga Olafimihan, Olanipekun Lanny Ntukidem, Inimfon Nsikak Jackson et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.620

620 Background: Testicular cancer is the most common malignancy among adolescent and young adult (AYA) males (15 – 40 years). While the median age at diagnosis is 33 years, testicular cancer also occurs in older aged males (&gt;40 years). Though it is less frequent in this population, it is important because outcomes of metastatic testicular cancer in this population are unknown. We examined the inpatient characteristics and outcomes for older patients with a diagnosis of metastatic testicular cancer. Methods: In a retrospective cohort analysis using the NIS database from 2008 to 2021, admitted patients with metastatic testicular cancer were identified using ICD codes. Descriptive analyses were conducted to compare sociodemographic, hospital-level and clinical characteristics between the older population and the AYA. Multivariate logistic and linear regression models were used to examine the association between the age groups and mortality, length of stay (LOS), and total hospital charges (THC). Results: There were 57,366hospitalizations with metastatic testicular malignancy. Of these, 14,733 (25.7%) were in the older male cohort. The mean age was 51 years in the older group and 27.3 years in the AYA group (P &lt; 0.001). There was a higher proportion of non-Hispanic White patients in the older group compared to the AYA group (73% vs 53%, P &lt; 0.001) but a lower distribution of Hispanic patients (11% vs 31%, P &lt; 0.001). Most of the patients in both cohorts had private insurance (54% vs 47%, P&lt;0.001). Both groups had most admissions in teaching (75.7% vs 84%, P &lt; 0.001), urban (95.2 vs 97.2%, P&lt;0.001), andlarge-sized hospitals (65.5 vs 70%, P=0.001). HIV comorbidity was higher in the older population (0.5% vs 0.2%, P = 0.02). The mortality rate was higher in the older population compared to the AYA population (6.2% vs 2.8%, P &lt; 0.001). The older group had over two-fold higher odds of mortality relative to the younger adult group (aOR: 2.25, 95% confidence interval [CI]: 1.84-2.75, P &lt; 0.001). On subgroup analysis, black patients had 70% higher mortality relative to non-Hispanic White patients (aOR: 1.7, 95% CI 1.15-2.5, p=0.008). There was a longer LOS in the older group (β coefficient: 0.49, 95% CI: 0.15-0.84, P = 0.005). THC were similar between the two cohorts (β-Coefficient: 1,238, 95% CI: -4,080–6,555, P = 0.65). The older group were less likely to have retroperitoneal lymph node dissection (aOR: 0.57, 95% CI: 0.48-0.67, P&lt;0.001). Conclusions: This is the largest epidemiological study to date on metastatic testicular cancer hospitalizations in older adults. Older males with metastatic testicular cancer have higher odds of mortality relative to younger patients. Racial disparities were evident, with Black patients having higher mortality. Our findings underscore unique characteristics and outcomes that could guide patient selection for future clinical trials and enhance the development of novel therapies for this population.

Implementing precision oncology in renal cell carcinoma (RCC): Prospective identification of clinical, tissue-based, and circulating factors to refine outcome prediction and support therapeutic choices (SIGNS-RCC TRIAL).

Journal of Clinical Oncology Ilaria Zampiva, Emanuela Fantinel, Veronica Mollica et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps617

TPS617 Background: At diagnosis, 55% of RCC are localized, and 25% are locally advanced/metastatic (aRCC); an additional 30% develop metastases during follow-up. Prognosis is highly variable in both resectable and advanced disease. All patients’ stratification tools are based on clinical risk scores. For resected patients, only pembrolizumab has demonstrated OS benefit in the adjuvant setting. For metastatic disease, first-line combos (IO-IO and IO-TKI) have dramatically improved outcomes in intermediate/poor-risk patients but have shown no additional OS benefit over TKI in good-risk patients. Methods: We designed a multicentric trial to identify novel prognostic/predictive biomarkers to refine current therapeutic algorithms for systemic therapy in both early-stage and aRCC in three different cohorts of patients. Cohort (A) includes patients who underwent radical surgery for RCC (resected, rRCC). Cohort (B) is a retrospective cohort that reclutes aRCC treated with VEGFR TKI monotherapy in I line. The prospective cohort (C) enrolls aRCC patients who are candidate to receive current I-line IO-TKI combos. In the first part, we will correlate patient- and tumor-related factors with the risk of recurrence after surgery for rRCC and progression-free survival and overall survival for aRCC. Tissue-based signatures will be obtained using IHC (PD-L1 expression, tumor immune microenvironment - TiME - composition), an NGS custom panel (mutational profiling), and FISH (for recurrent RCC alterations, such as 9p loss). Multiplex IHC and RNA-ISH will assess cytokine production by specific TiME components. Correlations between the obtained signatures and clinical outcomes will be calculated. In cohort C, the prognostic role of circulating factors (serum cytokine levels and mononuclear cell subpopulations, focusing on MDSC and TReg) will also be evaluated in addition to clinical and tissue-based factors. Blood samples will be collected before and during I-line treatment at pre-planned timepoints. Biomarkers will be quantitatively analyzed to evaluate their relationship with outcomes. Enrollment is ongoing.

The role of circulating kidney injury molecule-1 (KIM-1) in metastatic renal cell carcinoma (mRCC): A biomarker analysis of Tide-A, a phase 2 study of first-line avelumab (ave) plus intermittent axitinib (axi).

Journal of Clinical Oncology Chiara Ciccarese, Antonio Agostini, Martina Panebianco et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.584

584 Background: KIM-1 was evaluated as plasma circulating biomarker of microscopical residual disease, disease recurrence after nephrectomy, and potential benefit from adjuvant immunotherapy (IO). No data are available about its role in the metastatic setting. Tide-A is a phase 2 trial showing the feasibility of a de-intensified strategy of VEGFR-TKI interruption and IO-maintenance in mRCC pts treated with ave+axi. We investigated whether plasma KIM-1 was a prognostic biomarker in the prospective cohort of Tide-A. Methods: Treatment-naïve mRCC pts with prior nephrectomy, and no symptomatic/bulky/liver disease received ave+axi, and interrupted axi after 36 weeks in case of disease response. We performed a proteomics analysis with the aptamer-based technology SomaScan 7K (Somalogic, USA) to characterize the plasma expression levels of ≈7000 proteins. Levels of KIM-1 SomaScan aptamers (uniprot accession number Q96D42, aptamer ID:9021-1) were evaluated in available baseline samples and normalized by Adaptive Normalization by Maximum Likelihood (ANML) to integrate samples and correct for batch-effects. KIM-1 cut-off (10.456 relative fluorescence units [RFU]) was determined by Maximally Selected Rank Statistics using the maxstat R package, with Van der Waerden test and log-rank scores methods. Outcomes in pts with high vs. low KIM-1 levels at baseline were analyzed in the overall population, and adjusted for IMDC groups and for the duration of ave-maintenance. Results: Of 79 pts enrolled in Tide-A, data for KIM-1 analysis at baseline were available for 69 pts, of which 9 (13%) were KIM-1-high and 60 (87%) KM-1-low. KIM-1-high status was significantly associated with shorter OS (mOS 24.2 months [95%CI 21.1–NR] in KIM-1-high vs. not reached (NR) in KM-1-low; p=0.0019). The 2-yOS rate was 90% in KIM-1-low vs. 56% in KIM-1-high (p=0.002). Significant correlation between KIM-1 levels and OS was retained when adjusted for IMDC (table). No significant correlation was observed between KIM-1 levels and progression-free survival (mPFS 22.9 vs. 29.9 months in KIM-1-high and low, respectively; p= 0.4). Of the 29 pts that discontinued axi, KIM-1 data were available for 28 pts; the median duration of ave-maintenance was 15.9 wks in 25 pts with KIM-1-low and NR in 3 pts with KIM-1-high, (p=0.19). Conclusions: High baseline plasma KIM-1 level is an independent negative prognostic factor in metastatic RCC pts treated with VEGFR-TKI+IO combination, regardless from IMDC. KIM-1 seems not to have a key role in the selection of pts more likely to benefit from a TKI-intermittent strategy. Additional analyses are ongoing to identify predictive biomarkers to improve a tailored management of pts. 2-year OS rate according to IMDC. 2-year OS KIM-1 High KIM-1 Low P value IMDC Favourable 80% 95% 0.045 IMDC Int/Poor 25% 86% 0.006

Outcomes with multi parametric MRI (mpMRI) compared to diagnostic transurethral resection of bladder tumor (TURBT) in patients (pts) with suspected muscle-invasive bladder cancer (MIBC): A pilot study.

Journal of Clinical Oncology Nataliya Mar, Amanda Macaraeg, Ali Raad et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps881

TPS881 Background: TURBT is a standard diagnostic procedure to determine the depth of bladder tumor invasion into the bladder wall, particularly whether the muscularis propria layer is involved by tumor. This is crucial in order to distinguish between non-MIBC and MIBC, providing accurate tumor staging and determining appropriate therapy. However, TURBT may be associated with multiple complications such as pain, infection, need for Foley catheters, blood loss requiring transfusions, hospitalization, and a small mortality risk. A proportion of pts end up with a superficial resection out of concern for bladder perforation, where the muscularis propria layer is absent from the surgical specimen, and require a repeat TURBT that is typically performed 4-6 weeks following the initial procedure. Further, TURBT scheduling requires coordination with urology and operating room availability. These factors may cause delays in initiation of cancer-directed therapy. Recent data suggests that mpMRI may accurately predict the degree of invasiveness of bladder tumors by generating a Vesical Imaging-Reporting and Data System (VI-RADS) score. mpMRI is not commonly associated with complications and can be performed quickly by radiology. Methods: This is an IRB-approved, single-institution, prospective, single-arm, phase 2 pilot study, which aims to compare two diagnostic modalities for bladder cancer - TURBT versus mpMRI. Pts are identified based on tumor appearance during initial routine cystoscopy, if MIBC is suspected. If eligible for the study, pts then proceed with an mpMRI and a diagnostic TURBT. Primary study endpoint is incidence of concordance between VI-RADS score 4 and 5 bladder tumors on mpMRI, which represent “likely” and "very likely" muscularis propria invasion, and pathologic muscularis propria invasion on TURBT. Secondary study endpoints include time from initial cystoscopy to performing each diagnostic test, time from performing each diagnostic test to initiation of cancer-directed therapy, incidence of repeat TURBT, patient-assessed quality of life with each diagnostic test, incidence of adverse events related to each diagnostic test, progression free survival, and financial toxicity of each diagnostic test. Based on prior literature, the rate of detecting muscularis propria invasion with TURBT is about 90%. We hypothesized that diagnostic accuracy of mpMRI would be non-inferior to TURBT, within a 10% difference. Power calculations for this study were based on a one-sided, one-proportion exact test, with a power of 80% at a significance level of 0.05 using a non-inferiority design. Out of 30 anticipated pts, 11 have been enrolled to date. Clinical trial information: NCT06335667 .

Adolescent weight management counseling: The effectiveness of an online training program for primary healthcare professionals in Indonesia

PLoS ONE Fransisca H. Agung, Rini Sekartini, Nani Sudarsono et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0315770

Background Overweight and obesity are growing public health concerns globally for which innovative prevention and care delivery efforts are required. We recently developed a web-based training program to improve the quality of health professionals’ weight management counseling of adolescents in Indonesia. Having previously confirmed its acceptability, this study aimed to measure the effectiveness of the program through a randomized controlled trial. Methods We recruited 64 primary healthcare professionals from 17 provinces across Indonesia who were randomized to participate in a 4-week online training program (intervention group [IG, n = 32] or a waitlist control group [CG, n = 32]). Using active learning approaches, the training program focused on adolescent development, psychosocial assessment, motivational interviewing (MI), and parent engagement. Participants in each arm were asked to record two counseling sessions with adolescents. These were objectively rated by trained psychologists using a validated tool, and also by qualitative assessment of counseling quality. In both groups, the first recorded counseling session occurred before the training. The second recording took place after the training for IG participants, but not for CG participants. Results IG participants demonstrated significant improvements in their knowledge and counseling skills (p&lt;0.001, t-test). This included improvements in introductory remarks, quality of psychosocial assessment, and MI skills. There was no change in the extent of parental involvement. The MI training successfully oriented the counseling sessions towards a more collaborative and participatory conversation for supporting behavioral change. Conclusion This novel online training program improved the knowledge and counseling skills of Indonesian primary healthcare professionals. Greater emphasis on engaging parents and more guidance on conducting telehealth counseling may improve parental involvement in future iterations.

Advanced and hybrid machine learning techniques for predicting compressive strength in palm oil fuel ash-modified concrete with SHAP analysis

Scientific Reports Tariq Ali, Kennedy C. Onyelowe, Muhammad Sarmad Mahmood et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89263-y

Breaking language barriers: ‘Not being fluent in English is often viewed as being an inferior scientist’

Nature Mariana Lenharo Feb 10, 2025 DOI: 10.1038/d41586-025-00157-5

Domain-specific large language model for predicting prostate cancer treatment plan.

Journal of Clinical Oncology Umar Ghaffar, Amara Tariq, Mouneeb Choudry et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.428

428 Background: Prostate cancer management presents a significant healthcare burden, with the need to efficiently triage patients for treatment. Our objective is to leverage large language models to predict physician-recommended treatment plans from unstructured clinical notes. By accurately predicting treatment plans, we aim to risk stratify and triage patients effectively, thereby optimizing the allocation of physician resources. Methods: 448 unstructured initial urology consultation patient notes following first positive prostate cancer biopsy were identified. The recommended and final treatments received were manually annotated to establish ground truth labels (Table 1). The dataset was split 80:20 for training and testing, preprocessed to remove plan sections and formatted into question-answer (QA) format. A domain-specific large language model (LLM) inspired by GPT and a specialized tokenizer (PCa- LLM) for prostate cancer terminology were developed. QA models were built using the PCa-LLM and compared with those using GPT-2 as the backbone to predict recommended and final treatments. Results: For the physician-recommended treatment plans, our LLM (PCa-LLM) showed superior performance with higher AUROC scores for curative vs. non-curative treatments (0.78 vs. 0.65), chemo-hormonal vs. other non-curative treatments (0.89 vs. 0.65), and surveillance vs. all other treatments (0.72 vs. 0.70), while both models achieved the same high AUROC of 0.99 for chemo-hormonal vs. all other treatments. For final treatments, PCa-LLM demonstrated better AUROC for curative vs. non-curative treatments (0.77 vs. 0.74) and chemo-hormonal vs. other non-curative treatments (0.71 vs. 0.66), while GPT2 outperformed PCa-LLM for surveillance vs. all other treatments (0.78 vs. 0.70). Both models achieved an AUROC of 0.99 for chemo-hormonal vs. all other treatments. Conclusions: PCa-LLM accurately predicted most treatment categories better than GPT2, with higher AUROC scores, and can be utilized to triage prostate cancer patients using initial consultation notes. Task Physician -Recommended Treatment Plan Final Treatment Received Curative Prostatectomy/Radiation 228 230 Non-Curative Focal Therapy 22 15 Active Surveillance 40 45 Chemo-hormonal 30 30 Model Predictions (AUROC) GPT2 PCa-LLM GPT2 PCa-LLM Curative vs. non-curative 0.65 0.78 0.74 0.77 Chemohormonal vs. other non-curative 0.65 0.89 0.66 0.71 Chemohormonal vs. all other 0.99 0.99 0.99 0.99 Surveillance vs. other non-curative 0.64 0.60 0.67 0.59 Surveillance vs. all other 0.70 0.72 0.78 0.70

A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.

Journal of Clinical Oncology Syed A. Hussain, Jamie B. Oughton, Ruby Smith Whelan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.773

773 Background: BCG-unresponsive High-risk non-muscle invasive bladder cancer (HRNMIBC) tumours have an ominous prognosis and require effective, tolerable treatments. Uptake remains low for FDA approved agents (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln or N-803) due to toxicity concerns. We hypothesize direct intravesical administration of a PDL1 inhibitor could be effective with less systemic toxicity. However, it is unknown whether antibodies delivered via this route can reach tumor vasculature. INVEST is a phase Ib window of opportunity study investigating the safety and preliminary activity of passive instillation and direct injection of intravesical atezolizumab into the tumour/bladder wall. Methods: Eligible participants (ECOG performance status 0-2) are awaiting radical cystectomy (RC) for any stage urothelial cell carcinoma. Participants with muscle invasive bladder cancer, must be ineligible for/ refuse cisplatin based neo-adjuvant chemotherapy. Atezolizumab (600mg or 1200mg) is administered via direct injection into the tumour/bladder or by instillation into the bladder. The 3+3 design is utilised in the dose confirmation stages where participants receive either Single or Multiple (between 3 and 6) dose(s) of treatment before RC. Efficacy signals are derived from pathological complete response at RC and progression-free survival at 2 years. Primary endpoint, Dose confirmation stage: The number of dose-limiting toxicities (DLTs) observed from first dose of trial treatment to RC. Results: Enrolment began in May 2023. 13 participants were recruited to the single dose cohorts: 11 male, and 2 female. Age (Range; 43-86); median 70y, 9 NMIBC, 4 MIBC. 7 for direct injection (4 at 600mg and 3 at 1200mg dose) and 6 for passive instillation (3 at 600mg and 3 at 1200mg). Due to technical issues (syringe size) the first direct injection participant did not receive the full 600mg and were replaced. 12 participants received trial treatment as planned. There were no DLTs; 5 participants experienced non-trial treatment related SAEs (4 infections, 2 ileus, 2 renal impairment; 7/8 events occurred post-RC and all SAEs resolved). All participants underwent planned RC within the protocol stipulated timeline. Median time from last treatment to RC was18 days. 5 of 13 participants had downstaging of tumour in cystectomy specimen. Following independent Safety Review Committee review, recruitment is now open for the dose confirmation phase (Multiple 1200mg dose) in both treatment routes. Conclusions: Single dose atezolizumab treatment at a dose of 600mg and 1200mg in passive instillation and direct injection cohorts was well tolerated. Early efficacy data is encouraging. Multiple weekly doses of 1200mg in each treatment route are now being investigated within the INVEST trial. Clinical trial information: ISRCTN15842444 .

Using AI to identify optimal clinical, genomic, and radiographic prognostic features and novel risk classifiers compared to routinely available risk classifiers.

Journal of Clinical Oncology Benjamin Victor Tward, Skyler B Johnson, Jonathan David Tward Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.396

396 Background: This study investigated the use of artificial intelligence (AI) and traditional statistical techniques to identify and validate clinical (Clin), MRI-report-derived (MRIr), and genomic classifier (GC) features important for prognostic biomarker development and staging systems for prostate cancer metastasis. AI models were compared with conventional risk classifiers for prognostic accuracy. Methods: Data from 576 patients in a prospectively collected research registry, including 35 Clin, 1 GC, and 7 MRIr features, were used. Random forest (RF) classification and artificial neural networks (ANNs) using Leave-One-Out Cross-Validation evaluated the key features predictive of metastasis. Models with 35, 9, 6, or 0 Clin features were compared to those ± MRIr or GC features. ANN prognosticators from each model were fed into competing-risk regressions and compared to other established risk classifiers (CAPRA, STARCAP, 22-gene genomic assay (Decipher), Cell-Cycle Progression (CCP, Prolaris) score, and Combined Clinical Cell-Cycle Risk (CCR, Prolaris)) by the 5-year AUC (AUC5) for prognostic accuracy. Results: AI-derived models combining Clin ±GC +MRIr features (AUC5 range 0.72-0.76) outperform models excluding MRIr features (AUC5 0.66-0.71). AI models perform similarly to contemporary risk classifiers like Prolaris, CAPRA, STARCAP (AUC5 of 0.79. 0.77, 0.76, respectively (Table)). Models with 6 Clin, 4 MRIr, and a GC (Clin: Age, BMI, PSA, cT, alcohol use, and primary Gleason score; MRIr: prostate volume, max tumor diameter, extracapsular spread, and lymphadenopathy suspicion; GC: CCP score) performed as well as conventional classifiers. The classifier with the best ability to prognosticate early metastasis was Prolaris (AUC5 0.79). Conclusions: The findings indicate that AI biomarker discovery pipelines, integrating Clin, MRIr, and GC features, can successfully identify new and previously identified prognostic factors. AI-derived models have similar accuracy in predicting metastasis compared to contemporary risk classifiers. Adding MRIr and GC features improves risk prediction of early metastasis in AI-trained models. Lifestyle factors may have an important role in metastasis. Total # Features Genomic Features Radiographic Features Clinical Features Time-Dependent Competing Risk Regression 3-Year AUC 5-Year AUC 35 Clinical Feature AI Models (n=576) 43 1 7 35 0.70 0.72 42 7 35 0.69 0.72 36 1 35 0.64 0.66 35 35 0.62 0.65 11 Clinical Feature AI Models (n=576) 16 1 6 9 0.72 0.76 15 6 9 0.71 0.75 10 1 9 0.67 0.71 9 9 0.67 0.70 6 Clinical Feature AI Models (n=576) 11 1 4 6 0.73 0.75 10 4 6 0.73 0.75 7 1 6 0.61 0.64 6 6 0.62 0.65 0 clinical feature AI Models 7 1 6 0 0.66 0.68 6 6 0 0.65 0.67 Prolaris (n=570) 6 1 5 0.75 0.79 STARCAP (n=566) 5 5 0.72 0.77 CAPRA (n=570) 6 6 0.72 0.76 CCP score (n=576) 1 1 0.73 0.74 Decipher (n=25) 1 1 0.40 0.29

Updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2.

Journal of Clinical Oncology Jeffrey S Johnson, Mayer N Fishman, Michael J Schell et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.554

554 Background: The CM 214 trial with Nivolumab-ipilimumab recently presented its long term follow up results with regards to efficacy and safety. In this abstract, we similarly present extended 6 year follow up results of efficacy, safety, and correlative data from the phase 2 clinical trial combining IL-2 and short course pembrolizumab (pembro) for patients (pts) with metastatic renal cell carcinoma (mRCC). Methods: This phase 2 study included pts with untreated clear cell mRCC and ECOG 0-1 status. Pts were treated with a maximum of four 9-week blocks of pembro/IL-2. Pembro was dosed every 3 weeks throughout all four blocks without subsequent maintenance dosing. High dose IL-2 was administered only during blocks 2 and 3. At fixed time points, proteomic data via Olink and gene expression data via Nanostring were obtained for correlative analysis. The Kaplan-Meier method was utilized to determine updated overall survival (OS), progression-free survival (PFS), and treatment-free survival (TFS). TFS was defined as the time from completion of pembro/IL-2 to initiation of next therapy, date of last follow up if no subsequent line of therapy, or death. TFS was used to subdivide pts into extreme responders ( &gt; 5 years with no further treatment), non-responders ( &lt; 6 months until next line of therapy), and others. Proteomics and gene expression in extreme responders, non-responders, and others were compared via Wilcoxon rank sum test and logarithmic fold change in expression. Results: 27 pts were enrolled in the study with 26 receiving treatment. The number of pts with IMDC risk of favorable, intermediate, and poor were 6, 19, and 1, respectively. The median time from the on-study date to last known alive or expired was 73 months (range: 13-86). OS probabilities for 1-, 3-, and 5-year intervals were 100% (95% confidence interval [CI]: 100-100%), 76.9% (CI: 55.7-88.9%), and 73.1% (CI: 51.7-86.2%) respectively. PFS at 1-, 3-, and 5-year intervals were 61.5% (CI: 40.3-77.1%), 42.3% (CI: 23.5-60.0%), and 42.3% (CI: 23.5-60.0%) respectively. TFS probabilities for 1-, 3-, and 5-year intervals were 76.9% (CI: 55.7-88.9%), 42.3% (23.5-60.0%), and 42.3% (23.5-60.0%) respectively. Of the 11 pts with durable disease control not requiring any further systemic therapy, none had persistent adverse events at the grade 2 or higher level. In a comparison of extreme responders to non-responders, IL-8 was found to have a 1.43 log fold change in expression with a p-value of 0.019 detected by the Nanostring assay. Additionally, ADA and GZMH showed -0.82 and -1.57 log fold change in expression detected via Olink assay with p-values of 0.002 and 0.039 respectively. Further correlative data will be presented at the meeting. Conclusions: Short course pembro in combination with high dose IL-2 allows for durable immune response. At 6 years median follow up, &gt; 40% of pts have extended disease control without persistent toxicity or need for further systemic therapy. Moreover, we highlight select biomarkers that could be associated with this long-term response. Clinical trial information: NCT02964078 .

Healthcare utilization during acute medically attended episodes of respiratory syncytial virus-related lower respiratory tract infection among infants in the United States

PLoS ONE Jason R. Gantenberg, Robertus van Aalst, David R. Diakun et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0313573

Background Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States. Understanding healthcare utilization associated with medically attended (MA) RSV lower respiratory tract infection (LRTI) might inform research priorities aimed at reducing RSV-associated pediatric morbidity. We described healthcare utilization during acute MA RSV LRTI episodes within a geographically diverse cohort of infants in the United States. Methods We created retrospective cohorts of infants born in the United States from July 1, 2016 through February 29, 2020 in each of three de-identified insurance claims datasets: Merative MarketScan Commercial Claims and Encounters, Multi-State MarketScan Medicaid, and Optum’s de-identified Clinformatics ® Data Mart. We identified infants’ first MA RSV LRTI diagnosis during their first RSV season and followed them for 7 subsequent days to record outpatient, emergency department, and inpatient hospital utilization. We calculated the number of outpatient visits, emergency department visits, and inpatient hospital stays occurring during this acute episode and estimated the proportion of episodes involving ≥ 2 visits to a given healthcare setting. Results In the CCAE database, we identified 25,409 acute MA RSV LRTI episodes under the specific RSV definition and 69,068 under the sensitive definition. In the MDCD database, these totals were 67,357 and 170,744, while in the CDM database, they were 12,402 and 31,363, respectively. Across data sources, 34%–69% of infants’ first acute MA RSV LRTI episodes involve 2 or more visits to a healthcare setting within 7 days. The percentage of episodes involving at least 2 visits ranged from 34–62% among healthy term infants, 38–65% for Palivizumab-eligible infants, and 38–69% for infants with other comorbidities. Conclusions Within a week of their first MA RSV LRTI diagnosis, infants frequently experience at least 2 visits to one or more healthcare settings, regardless of their comorbidity profile. The percentage of MA RSV LRTI episodes involving at least 2 visits to a healthcare setting may vary by insurance claims database, even between commercial payers.

Spatiotemporal characteristics of gait when walking on an uneven surface in children with cerebral palsy

Scientific Reports Cloé Dussault-Picard, Yorsa Cherni, Philippe C. Dixon Feb 10, 2025 DOI: 10.1038/s41598-025-89280-x

‘Devastating’ cuts to NIH grants by Trump’s team put on hold by US judge

Nature Max Kozlov, Dan Garisto, Heidi Ledford Feb 10, 2025 DOI: 10.1038/d41586-025-00436-1

Formula-01: A phase Ⅱ study of disitamab vedotin (RC48) intravenous injection combined with BCG intravesical instillation in high-risk non-muscle invasive bladder cancer with HER2 high expression.

Journal of Clinical Oncology Xingliang Tan, Yanjun Wang, Zhiming Wu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps894

TPS894 Background: Intravesical instillation of bacillus Calmette-Guérin (BCG) is the first-choice treatment for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC). However, our previous study has demonstrated that HER2 was an independent predictor of poor BCG efficacy in NMIBC (Tan et al., European Urology Oncology, 2023). We found that high-risk NMIBC patients with HER2 high expression had the highest risk of disease recurrence and progression with 46.9% 2yr-RFS rate and 23.0% 2yr-PFS rate. Disitamab Vedotin (RC48) is an antibody-drugconjugate(ADC) targeting HER2 with a payload of MMAE. Formula-01 will evaluate the efficacy and safety of RC48 combining with BCG instillation in HER2 overexpression high-risk NMIBC patients. Methods: Formula-01 is an open-label, non-randomized, phase 2 trial. Patients must receive complete transurethral resection (TURBT) of bladder tumor (R0 resection) and did not accept BCG intravesical instillation and neoadjuvant chemotherapy or radiotherapy before. NMIBC was pathologically confirmed for all patients according to the 8th edition of the TNM staging system and the risk stratification was recorded basing on the American Urological Association (AUA)/Society of Urologic Oncology (SUO) guidelines.The pathology of NMIBC must be pure urothelial carcinoma and any divergent differentiation subtypes are excluded. This study is open at the Sun Yat-sen University Cancer Center (SYSUCC) and 70 patients are enrolled. The single-arm cohort will receive RC48 intravenous injection (2.0 mg/kg, iv drip, d1, Q2W, 8 cycles) combining with BCG intravesical instillation at least one year (D2PB302 strain, 1.2×10 8 CFU, 120 mg, dissolved in 40–50 ml of saline, 19 times in 1 yr). The primary endpoint is 2yr-RFS rate. Secondary endpoints include 1yr-RFS, 1yr-PFS, 2yr-PFS rate, bladder retention rate and safety. Exploratory analyses include determination of Her2 expression, molecular subtypes. The sample size calculation is based on the historical results of specific subgroup patients with 2yr-RFS rate of 46.9%, and we expected improvements to 70.0%. One-sample long-rank test was used to calculate the enrollment of 70 patients (α=0.05, β=0.8, lost-to-follow-up rate of 5.0%). The study began enrollment in February, 2024 and completed enrollment in October, 2024. Research approval was obtained from the SYSUCC Ethics Committee. Clinical trial information: ChiCTR2400080767 .